lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Since all investors are in the same boat it makes 100% sense that those with money will continue to fund the company until global approval. That's why Thermo gave the company additional funding as well as the other angel investors who are doing the same.
Sunk cost avoidance dictates they take this rational action. Those who claim Northwest has financing issues thus could be at risk of bankruptcy are absolute lunatics as the large shareholders are not going to abandon the company or their investment at this very late stage in the approval process.
The author thinks we are filing an NDA. He then shills for another company. We are dealing with idiots.
The evidence is overwhelming.
I expect regulatory submission if not approval by Q4 2023 with combination trials announced concurrently. The trial may take longer than my estimate but I still believe large settlement offers will be given by the defense after MTD denial. Q1 or Q2 2024 at the latest.
I think the biggest question would be whether management will seek a trial once they've secured financing from a partner to engage in combination trials? One could argue an infusion in cash will instantly raise the value of the company yet after that's been achieved through a partnership then management will likely prefer a trial.
I suspect they have while who knows what DOJ are doing right now?
As Thermo made it clear all shareholders in NWBO including management are in the same boat. We sink or swim all together. The notion that management are given preference to large shareholders has zero basis in reality. This is simply a conspiracy theory.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172619501
That's a ridiculous conclusion. Management are not trying to dilute the company at this depressed level which can be readily seen in their prudent use of C shares. The majority of them have not been sold. If management wanted to help out their large investor friends, as you say, they would be selling many more now.
In fact they have not because they know the value of the company will increase immensely soon. We have seen many non dilutive sources of financing from the gain contingency derivative to the many non convertible short term loans issued over the past couple of years. The evidence does not support your irrational statements.
As Dave Innes told me recently think deeply before you send a "nastygraham" as that only reflects poorly on your judgment while it also damages the company through killing animal spirits.
I agree
Have to wonder how many years in jail the criminals will face for manipulating Northwest Biotherapeutics!
If not for the manipulation we would be $10B company today.
Never been more confident.
I am a retail shareholder with zero ties to anyone at Northwest.
10Q showed we are in discussions with BP.
In my opinion you are 100% wrong.
You mean the low volume manipulation in the last few minutes of trading?
Manipulation ongoing that's for sure.
That's right.
Wow, such genius!
In reality management have been prudent minimizing dilution. The latest 10Q showed they've barely sold any C shares with nearly 9 million out of 10 million emaining. That's enough to raise $2B in cash once we get to $10.
Let Lex Luther know he's going down soon.
You are contradicting Marnix Bosch at ASCO 2022 and the Sawston build out outlined in many SEC filings. Sawston facility can expand to 1200 patients a month if demand requires. I don't expect this to happen right after UK approval but it should be possible one year after global approval by all 4 trial regulators.
Most drastic increase in price will come with sudden notification of approval.
I believe we won't have any PR until MAA approval for DCVax.
Guy who doesn't know that strike price = exercise price has lost all credibility on this forum.
Sawston can handle 1200 patients a month according to the 2022 manufacturing presentation given by Marnix Bosch at ASCO.
Government does not regulate the capacity of a drug manufacturer. They base approval on whether the product works in the context of side effects.
Well said. I agree. The FDA doesn't care about manufacturing capacity but quality control for the products it approves on the basis of safety and efficacy.
Poor Man works for Milken.
That's right Roman!
Where in the 10Q does it state that supply chain issues are preventing MHRA approval or commercial scale up to meet demand? In fact you won't find it in the quarterly as you're fabricating that narrative.
Yes they're likely using patients for R&D purposes related to approvals. Thus this isn't profitable because investment in the process isn't yet complete. We will see massive ROIC when MHRA approves DCVax as Sawston can handle 12K patients per year. That's about $2B in annual revenue. Our company has an insignificant amount of debt. Again massive return on invested capital.
The company.
Net after R&D expenses. Perhaps some patients are getting a subsidy as the firm have further "real world" research they are doing while administering the vaccine? Maybe some of these patients are being used to validate Flaskworks?
As much as I thought we would see a large revenue increase under Specials that isn't the case. Though that shouldn't be a concern as the firm are funded through approvals.
Sawston has manufacturing capacity for 12K patients a year. Once we see MHRA approval this whole distraction will seem quite irrelevant!
Given it seems the NICE appraisal has began then this CRO work likely are being done for their QALY analysis.
If you have such questions then contact management instead of raising speculations on this message board. Rumors only harm all investors in Northwest Biotherapeutics.
I am going to let them continue their work then the results speak for themselves.
Management are not going to change strategy at this point while they're defending the stock price by pushing through approval as well as the lawsuit. They already own hundreds of millions in shares while discussions are underway on combination trials. If successful these will substantially increase the stock price. If you are having a bad day then think before you type which was great advice I got from Dave Innes today.